GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (OTCPK:XVIPF) » Definitions » Future 3-5Y Total Revenue Growth Rate

XVIPF (Xvivo Perfusion AB) Future 3-5Y Total Revenue Growth Rate : 28.61 (As of Apr. 13, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Xvivo Perfusion AB Future 3-5Y Total Revenue Growth Rate?

Future 3-5Y Total Revenue Growth Rate is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Xvivo Perfusion AB's Future 3-5Y Total Revenue Growth Rate is 28.61.


Competitive Comparison of Xvivo Perfusion AB's Future 3-5Y Total Revenue Growth Rate

For the Medical Devices subindustry, Xvivo Perfusion AB's Future 3-5Y Total Revenue Growth Rate, along with its competitors' market caps and Future 3-5Y Total Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xvivo Perfusion AB's Future 3-5Y Total Revenue Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Future 3-5Y Total Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's Future 3-5Y Total Revenue Growth Rate falls into.


;
;

Xvivo Perfusion AB  (OTCPK:XVIPF) Future 3-5Y Total Revenue Growth Rate Explanation

Future 3-5Y Total Revenue Growth Rate is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.


Xvivo Perfusion AB Future 3-5Y Total Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Xvivo Perfusion AB's Future 3-5Y Total Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Xvivo Perfusion AB Business Description

Traded in Other Exchanges
Address
Gemenskapens gata 9, Molndal, SWE, SE-431 53
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.

Xvivo Perfusion AB Headlines

From GuruFocus

Xvivo Perfusion AB Corporate Analyst Meeting Transcript

By GuruFocus Research 02-15-2024

Q3 2024 Xvivo Perfusion AB Earnings Call Transcript

By GuruFocus News 10-25-2024

Interim Report January - June 2024

By ACCESSWIRE 07-13-2024

Q1 2023 Xvivo Perfusion AB Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q4 2024 Xvivo Perfusion AB Earnings Call Transcript

By GuruFocus News 02-07-2025

Q4 2022 Xvivo Perfusion AB Earnings Call Transcript

By GuruFocus Research 02-15-2024

Conference Call on Interim Report

By ACCESSWIRE 10-10-2024

Q3 2022 Xvivo Perfusion AB Earnings Call Transcript

By GuruFocus Research 02-15-2024

Interim report January-March 2024

By ACCESSWIRE 04-24-2024

Conference call on Interim Report

By ACCESSWIRE 06-25-2024